Gastrectomy Alone or in Combination With Hepatic Resection in the Management of Liver Metastases From Gastric Cancer: A Systematic Review Using an Updated and Cumulative Meta-Analysis. by Gavriilidis, Paschalis et al.
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press Inc™   |   www.jocmr.org
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
600
Original Article J Clin Med Res. 2019;11(8):600-608
Gastrectomy Alone or in Combination With Hepatic 
Resection in the Management of Liver Metastases  
From Gastric Cancer: A Systematic Review  
Using an Updated and Cumulative Meta-Analysis
Paschalis Gavriilidisa, b, d, Keith J. Robertsb, Nicola de’Angelisc,  
Robert P. Sutcliffeb
Abstract
Background: Recent studies have demonstrated that hepatectomy in 
patients with synchronous hepatic gastric metastases may improve 
survival in certain patients. This study aimed to evaluate survival ben-
efits of gastrectomy plus hepatectomy versus gastrectomy alone in 
patients with hepatic gastric metastases.
Methods: Studies were identified by a systematic search of Embase, 
PubMed, Cochrane Library, and Google Scholar databases. Tradition-
al and cumulative meta-analyses were used to monitor the evidence 
over time.
Results: Eleven studies which included 861 patients compared gas-
trectomy plus hepatic resection in 349 patients with gastrectomy 
alone in 512 patients. Overall significantly better survival rates of 
1, 2, 3, and 5 years were demonstrated for patients who underwent 
gastrectomy plus hepatic resection compared to patients who un-
der underwent gastrectomy alone ((hazard ratio (HR) = 0.52 (0.39, 
0.69), P < 0.001), (HR = 0.85 (0.74, 0.97), P = 0.01), (HR = 0.80 
(0.72, 0.90), P = 0.003), (HR = 0.83 (0.78, 0.90), P < 0.001), re-
spectively).
Conclusions: Carefully selected patients with hepatic gastric metas-
tases may benefit from hepatic resection.
Keywords: Hepatic metastases; Gastric adenocarcinoma; Hepatec-
tomy; Gastrectomy
Introduction
Gastric cancer has a poor prognosis and it is the second most 
common cause of cancer deaths worldwide [1]. At the time of 
diagnosis, only 30% of the patients are suitable for curative 
treatment [2]. Synchronous hepatic metastases are diagnosed 
in 3% to 14% of the patients [3, 4], while metachronous vari-
ants appear in 37% of patients after curative gastrectomy [5]. 
Current evidence recommends supportive therapy and pal-
liative chemotherapy for patients with peritoneal spread and 
distant metastases [6]. The results of a randomized phase 3 
trial conducted in Japan, South Korea and Singapore com-
pared the survival benefits of gastrectomy followed with 
chemotherapy against chemotherapy alone in patients with 
advanced cancer and with a single non-curable factor con-
fined either to the peritoneum, liver, or para-aortic lymph 
nodes (16a1/b2). The result did not demonstrate any survival 
benefits from the gastrectomy [7]. Therefore, gastrectomy 
cannot be justified as a treatment option for that group of 
patients.
Recent meta-analysis demonstrated survival benefits of 
hepatic resection in cases of hepatic gastric metastases in care-
fully selected patients [8].
The aim of the present study is to evaluate the survival 
benefits of the gastrectomy plus hepatectomy (GH) compared 
with gastrectomy (GA) alone for cases of hepatic metastases 
from gastric adenocarcinoma using traditional and cumulative 
meta-analyses.
Materials and Methods
This systematic review and meta-analysis was carried out 
in accordance with the guidelines set out in the Preferred 
Reporting Items for Systematic Review and Meta-Analysis 
(PRISMA) checklist [9]. The article does not contain any 
studies with human or animal subjects performed by any of 
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the authors.
Literature search
A systematic literature search of articles published in the 
last 30 years was performed using the Embase, MEDLINE 
(PubMed), Cochrane library, and Google Scholar databases, 
using free text and MeSH search terms (gastric cancer, gas-
trectomy, hepatic or liver gastric metastases, hepatectomy or 
liver resection for gastric metastases, stomach neoplasms). A 
grey literature search of the clinicaltrials.gov website was also 
performed. References in the retrieved articles were checked 
manually and further analyzed. Disagreements between au-
thors were resolved by consensus.
Study selection, inclusion and exclusion criteria
Cohort or retrospective studies, and case-matched studies that 
evaluated the results of the patient undergoing any form of liv-
er resection for liver gastric adenocarcinoma, in the absence of 
peritoneal metastases were included in the study. All reviews, 
narrative articles, cohort studies with less than 10 patients, 
extrahepatic metastases, malignancies other than gastric ad-
enocarcinoma with liver metastases, studies with insufficient 
data regarding survival outcome after liver resection and non-
English language publications were excluded.
Data extraction and outcomes
Two reviewers (PG and KR) independently extracted the fol-
lowing summary data for the included studies: name of authors; 
number of patients; age; gender; synchronous, metachronous, 
unilobar, bilobar, solitary and multiple liver metastases; neo-
adjuvant and adjuvant therapy; morbidity; median follow-up 
time; median survival; 1-, 2-, 3-, and 5-year overall survival; 
and 30-day mortality. Primary outcomes were 1-, 2-, 3-, and 
5-year overall survival.
Assessment of included studies
Two authors (PG, KR) independently assessed the quality of 
evidence provided by each study using the Oxford Center for 
Evidence-Based Medicine scoring system [10]. Moreover, the 
methodological qualities of all retrospective comparative stud-
ies were assessed with the validated Newcastle-Ottawa Scale 
(NOS) [11]; studies that scored ≥ 7 were considered of high 
quality. NOS is an assessment tool used to measure the quality 
of retrospective studies included in a systematic review and 
meta-analysis. Using this tool, each study was assessed using 
eight parameters, categorized into three groups: first, the se-
lection of the study groups; second, the comparability of the 
groups; and third, the ascertainment of either the exposure or 
outcome of interest for case-control studies, respectively. One 
point was awarded for each quality item. The highest quality 
studies were awarded up to nine points [11].
Statistical analysis
Statistical analysis was conducted using Review Manager 5.3 
software (Cochrane Collaboration, Oxford, England). Hetero-
geneity was assessed through the I2 statistic and cut-off values 
of 25%, 50%, and 75% were considered low, moderate, and 
high, respectively [12]. In such cases, both fixed- and random-
effects models were produced, and the conclusions compared, 
with the latter used preferentially in cases where there were 
discrepancies between the two models. In cases of I2 values 
less than 25%, fixed-effects models were used throughout.
Dichotomous variables were analyzed based on odds ratios 
(ORs) with 95% confidence intervals (CIs). For the analyzed 
outcomes, the reference categories were selected so that OR < 
1 favored hepatectomy. Continuous variables were combined 
based on both the mean difference (MD) and the standardized 
mean difference (SMD). For studies that did not report the mean 
and variance for the two groups, these values were estimated 
from the median, range, and the size of sample where possible, 
using the technique described by Hozo et al [13].
Analysis of long-term survival was performed by combin-
ing the hazard ratios (HRs) and 95% CIs from the included stud-
ies. These were rarely reported, and so were estimated using the 
method described by Parmar et al [14], where this was possible. 
Studies that reported the numbers at risk were combined with ei-
ther the quoted survival rates or values read from enlarged plots 
of the Kaplan-Meier curves to produce the estimates. Where 
numbers at risk were not quoted, constant censoring over the 
period of follow-up was assumed in the estimation. The studies 
were weighted using an inverse variance approach and HRs < 1 
favored the hepatectomy plus gastrectomy approach.
In all analyses, the significance level was set at P < 0.05. 
Cumulative meta-analysis was conducted using STATA soft-
ware (version 15, Stata Corp LP, TX, USA).
Sensitivity analysis
Analyses of outcomes were conducted using both random-
effects and fixed-effects models in order to assess the impact 
of heterogeneity on the results. Moreover, subgroup analyses 
of the eastern and western studies were performed. Publica-
tion bias was not estimated because less than 10 studies were 
included in each outcome [15]. Cumulative meta-analysis was 
performed to detect the accumulation of evidence over time.
Results
Search strategy and included study characteristics
Forty-three studies, which included 1,198 patients, who under-
went hepatic resection for hepatic metastases from gastric ad-
enocarcinoma, were selected from a pool of 1,329 studies (Fig. 
1) [3, 4, 22, 16-55]. Of these 43 studies, 11 studies comprised 
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of 861 patients compared gastrectomy plus hepatic resection 
(349 patients) to gastrectomy without hepatic resection (512 
patients). Two studies were excluded because of incomplete 
reporting of outcomes.
The quality of evidence of all 43 studies were assessed as 
type 2b using the Oxford Center for Evidence-Based Medicine 
scoring system.
All 11 studies comparing gastrectomy plus hepatic resec-
tion to gastrectomy alone scored more than seven stars in the 
NOS and were therefore characterized as being of high quality 
(Supplementary Table 1, www.jocmr.org).
Results of the 43 studies included in qualitative synthesis
The median age of the 1,198 patients who underwent hepatic 
resection was 64 (25 - 89), the majority of whom were men 
752 (63%). Eight percent (8%) of the patients in these various 
studies underwent neoadjuvant chemotherapy, whereas 48% of 
them underwent adjuvant chemotherapy. Six hundred and sev-
en (62%) patients underwent resection for synchronous metas-
tases and 376 (38%) for metachronous metastases. Unilateral 
metastases occurred in 525 (74%) patients and 188 (26%) pa-
tients have bilateral metastases. Five hundred and forty (59%) 
patients underwent resection for solitary tumors and 377 (41%) 
for multiple tumors. Minor hepatectomies were performed in 
74% of patients. Morbidity was 26% (with a range of 0% to 
60%) and the 30-day mortality was 0 (0% to 30%).
The median 1, 2, 3, 5-year survival was 68%, 29.5%, 32% 
and 27%, respectively with a median survival of 21 (9 - 52) 
months.
Cumulative meta-analysis
Cumulative meta-analysis demonstrated that there were no 
studies which indicate the particular impact on the results over 
time. In the dichotomous variables of synchronous/metachro-
nous and solitary/multiple metastases, turning points on the 
accumulation of evidence over time were identified. Particu-
larly, in the synchronous/metachronous forest plot, two time 
periods were depicted. One ranged from 1994 to 2014 when 
nonsignificant differences were demonstrated and a second pe-
riod starting from the study of Sinohara et al in 2015 [52] until 
present when it was demonstrated that significantly less me-
tachronous metastases compared to synchronous cases were 
Figure 1. Flow diagram of the search strategy.
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included (Fig. 2). Similarly, the time period between 1994 and 
2003 is depicted by solitary/multiple forest plots when demon-
strably nonsignificant differences exists between solitary and 
multiple metastases in the included studies. A second period 
starting in 2003 with the study of Shirabe et al [24] and lasting 
until present time, demonstrates that significantly less multiple 
metastases compared to solitary ones were included (Fig. 3).
Meta-analysis of studies comparing GH against GA
Tumor characteristics
There were no significant differences in the proportion of syn-
chronous metastases between the GH and GA groups. Similarly, 
there were no significant differences in the proportion of me-
tachronous metastases between GH (28%) versus GA (29%) 
groups. The proportion of patients with unilobar distribution 
was significantly higher in the GH (58%) than in the GA (25%) 
groups. There was no significant difference in the proportion of 
solitary metastases between the GH cohort and GA cohort (Ta-
ble 1).
Primary outcomes 1-, 2-, 3-, and 5-year overall survival
Patient survival for 1-, 2-, 3-, and 5-year was found to be sig-
nificantly better in GH cohort compared to the GA group (Ta-
ble 1) (Fig. 4).
Discussion
This updated traditional and cumulative meta-analysis consists 
of 43 studies which included 1,198 patients with a median age 
of 64 (25 - 89) years, the majority of whom were men ac-
counting for 63%, compared to 27% who were women. Syn-
chronous metastases cases were 62% and metachronous cases 
38%. Unilobar cases were 74% and bilobar 26%. Patients with 
solitary lesions were 59% while those with multiple lesions 
were 41%. The 30-day overall mortality was 0% (0-30%) and 
the median survival period was 21 (9 - 52) months. The 1-, 
2-, 3-, and 5-year overall survival was 68% (39-96%), 29.5% 
(25-50%), 32% (14-70%), and 27% (9-60%), respectively. The 
updated results of the present study did not show any signifi-
cant difference when compared with the results of the previous 
meta-analysis [8].
Interestingly, CMA depicted turning points in the accu-
mulation of evidence over time. The traditional meta-analysis 
demonstrated that significantly less metachronous metastases 
were included in the studies; on the contrary the CMA reveals 
that its effect size was nonsignificant for the period from 1994 
to 2014, the second period starts in 2015 until present day and 
it demonstrates that significantly more synchronous metastases 
were included compared to metachronous. Similarly, discrep-
ancies between the traditional and CMA were demonstrated in 
the evaluation of solitary/multiple metastases (Figs. 2, 3). The 
Figure 2. a) Traditional meta-analysis of synchronous/metachronous metastases demonstrates that significantly less metachro-
nous metastases were included compared to synchronous metastases. b) Cumulative meta-analysis of synchronous/metachro-
nous metastases depicts two time periods, one from 1994 to 2014 when nonsignificant differences were demonstrated and a 
second from 2015 until present when it was demonstrated that significantly less metachronous metastases compared to syn-
chronous cases were included.
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Figure 3. a) Traditional meta-analysis of solitary/multiple metastases demonstrates that significantly less multiple metastases 
were included compared to solitary metastases. b) Cumulative meta-analysis of solitary/multiple metastases depicts two time 
periods, one from 1994 to 2003 when nonsignificant differences were demonstrated and a second from 2003 until present when 
it was demonstrated that significantly less multiple metastases compared to solitary cases were included.
Table 1.  Outcomes of Interest
Outcome of interest Number of studies and pa-tients (%; events/total)
Statistical method, esti-
mated effect, 95% CI
P value I2 (%)
Age 4, 244 MD = -2.40 (-6.13 to 1.34) 0.23 57
Synchronous metastases 4, 206 (54%; 56/104) (51%; 52/102) OR = 0.42 (0.02 to 8.50) 0.57 89
Metachronous metastases 4, 206 (28%; 29/104) (29%; 30/102) OR = 1.72 (0.86 to 3.43) 0.12 85
Unilobar metastases 6, 430 (58%; 92/159) (25%; 67/271) OR = 3.88 (2.43 to 6.19) < 0.001 0
Bilobar metastases 6, 430 (26%; 41/159) (49%; 133/271) OR = 0.27 (0.08 to 0.91) 0.04 83
Solitary metastases 5, 320 (52%; 64/124) (36%; 71/196) OR = 2.98 (0.95 to 9.37) 0.06 70
Multiple metastases 5, 320 (33%; 41/124) (66%; 129/196) OR = 0.17 (0.04 to 0.80) 0.02 83
1-year OS 9, 637 HR = 0.52 (0.39 to 0.69) < 0.001 39
2-year OS 4, 397 HR = 0.85 (0.74 to 0.97) 0.01 44
3-year OS 9, 637 HR = 0.80 (0.72 to 0.90) 0.003 58
5-year OS 7, 452 HR = 0.83 (0.78 to 0.90) < 0.001 0
Subgroup analysis East versus West
1-year OS East 6, 306 HR = 0.42 (0.28 to 0.65) < 0.001 34
1-year OS West 3, 331 HR = 0.63 (0.43 to 0.91) 0.01 47
2-year OS West 3, 331 HR = 0.85 (0.71 to 1.01) 0.07 53
2-year OS East 1, 66 HR = 0.80 (0.65 to 1.00) 0.05 0
3-year OS East 6, 306 HR = 0.78 (0.70 to 0.86) < 0.001 0
3-year OS West 3, 331 HR = 0.85 (0.69 to 1.05) 0.13 67
5-year OS East 5, 272 HR = 0.84 (0.78 to 0.91) < 0.001 5
5-year OS West 2, 180 HR = 0.80 (0.68 to 0.94) 0.008 0
OS: overall survival; MD: mean difference; HR: hazard ratio; OR: odds ratios.
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above findings suggest that with the accumulation of evidence 
and experience, the selection of patients for hepatic resection 
became more meticulous and careful.
The pair-wise meta-analysis of 11 studies demonstrated 
that 1-, 2-, 3-, and 5-year overall survival was significantly 
better in gastrectomy plus hepatectomy cohort compared to 
gastrectomy alone cohort.
Subgroup analysis demonstrated that there was no evi-
dence of significant difference between Eastern and Western 
countries in 1-year overall survival (OS); both demonstrated 
significant results. Interestingly, 2-year OS was marginally 
nonsignificant in East and West when compared separately. 
However, this became significant when the two samples were 
compared together. There was evidence that eastern studies 
demonstrated significantly better 3-year OS compared to west-
ern studies. There were nonsignificant differences in 5-year OS 
between East and West; both demonstrated significant results 
(Table 1). Of note, Markar et al [8] evaluated hepatic resec-
tions concomitant and non-concomitant with gastrectomy and 
reported better survival benefits for the East compared to the 
West. It is apparent that the cohort of patients who underwent 
gastrectomy with associated hepatic resection were more care-
fully selected and this is the reason of similar survival benefits 
between the East and West.
The results of the present study should be interpreted in 
the context of its limitations. All the studies were retrospective 
including small numbers of patients carefully selected without 
extra-hepatic metastases. Therefore, selection, institutional, 
national bias, underpowered sample size and smaller oncologi-
cal burden may have influenced the results. Another caveat of 
Figure 4. Forest plot depicting 1-, 2-, 3-, 5-year overall survival of gastrectomy plus hepatectomy versus gastrectomy alone. It 
is depicting that the gastrectomy plus hepatic resection cohort demonstrated significantly better survival benefits compared to 
gastrectomy alone.
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this study is that very few studies reported detailed morbid-
ity data according to international classifications. Therefore, it 
was not possible to do meta-analysis of major morbidity.
Conclusions
The results of this study can justify the adjuvant role of hepatic 
resection for unilobar gastric liver metastases in carefully se-
lected patients.
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